Amid ongoing scrutiny of high pharmaceutical drug prices, debate about the value of “orphan drugs”—those designed to treat rare conditions that affect fewer than 200,000 individuals —continues to capture public and policy maker attention.
Read More...
Read the complete post at http://healthaffairs.org/blog/2017/05/04/orphan-drugs-pursuing-value-and-avoiding-unintended-effects-of-regulations/
Posted
May 04 2017, 08:10 AM
by
Health Affairs BlogHealth Affairs Blog